ID: h-2b25f4433e
Hypothesis
High baseline tau and ISR activation may lower the effective trazodone threshold, making biomarker-defined subgroups more responsive
Patients with elevated p-tau and ISR activation may require less trazodone exposure to show pharmacodynamic effects because the drug acts on an already engaged pathogenic node.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 3 oppose
🧪 Overview
Patients with elevated p-tau and ISR activation may require less trazodone exposure to show pharmacodynamic effects because the drug acts on an already engaged pathogenic node. The best use of this idea is as a stratification hypothesis nested within dose-finding studies rather than as a standalone efficacy thesis.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["MAPT/Tau Protein<br/>Microtubule Stabilizer"]
B["CDK5/GSK3B Activation<br/>Kinase Dysregulation"]
C["Tau Hyperphosphorylation<br/>Ser396/Thr231/Ser202"]
D["Tau Detachment<br/>Microtubule Destabilized"]
E["Tau Oligomers<br/>Paired Helical Filaments"]
F["Neurofibrillary Tangles<br/>Intraneuronal Inclusions"]
G["Axonal Transport Failure<br/>Synaptic Dysfunction"]
H["Neurodegeneration<br/>Tauopathy Spread"]
A --> B
B --> C
C --> D
D --> E
E --> F
D --> G
G --> H
F --> H
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix3 supports3 contradicts
Supports
Phosphorylated eIF2alpha is enriched in tau-positive degenerating neurons, linking ISR activation to tau pathology.
Supports
PERK pathway inhibition prevents tau-mediated neurodegeneration in preclinical systems, supporting pathway dependence in tauopathy.
Contradicts
High p-tau and high ISR activation may instead mark more advanced, less reversible disease rather than greater dose sensitivity.
Contradicts
No human evidence currently shows that biomarker-high patients respond at lower trazodone doses.
Contradicts
Apparent subgroup effects could reflect regression to the mean or larger biomarker dynamic range rather than true threshold lowering.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — MAPT;
No curated PDB or AlphaFold mapping for MAPT; yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for MAPT; EIF2AK3; EIF2S1; ATF4 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for MAPT; EIF2AK3; EIF2S1; ATF4.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0094
Events (7d)
1
Price History
▲1.1%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF patients with elevated baseline CSF p-tau181 (≥2x control mean) and peripheral ISR activation signatures (ATF4 transcriptional score or p-eIF2α in blood) are stratified to receive trazodone doses 5 | Biomarker-positive subgroup achieves equivalent neurodegeneration marker reduction at 50% lower trazodone dose, demonstrating leftward shift in dose-response cu | — no observation — | pending | 0.55 |
| IF patients entering trazodone dose-finding trials are stratified into high-ISR activation (plasma p-eIF2α/ATF4 gene expression ratio in top tertile) versus low-ISR activation cohorts, THEN the high-I | High-ISR activation group exhibits accelerated and amplified neurodegeneration biomarker decline: CSF NfL rate of change shifts from +5%/month (natural history) | — no observation — | pending | 0.48 |
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF patients with elevated baseline CSF p-tau181 (≥2x control mean) and peripheral ISR activation signatures (ATF4 transcriptional score or p-eIF2α in blood) are stratified to receive trazodone doses 50% below standard dosing, THEN they will demonstrate comparable or greater pharmacodynamic biomarker
Predicted outcome: Biomarker-positive subgroup achieves equivalent neurodegeneration marker reduction at 50% lower trazodone dose, demonstrating leftward shift in dose-r
Falsification: Biomarker-positive subgroup fails to show superior response at reduced dose; response magnitude is <25% of biomarker-negative group's standard-dose response, or dose-response analysis shows no signifi
pendingconf 48%
IF patients entering trazodone dose-finding trials are stratified into high-ISR activation (plasma p-eIF2α/ATF4 gene expression ratio in top tertile) versus low-ISR activation cohorts, THEN the high-ISR group will show earlier and larger pharmacodynamic responses (≥30% reduction in CSF NfL slope) wi
Predicted outcome: High-ISR activation group exhibits accelerated and amplified neurodegeneration biomarker decline: CSF NfL rate of change shifts from +5%/month (natura
Falsification: No significant interaction between baseline ISR activation status and trazodone dose on primary pharmacodynamic biomarker endpoints; high-ISR group response is not distinguishable from low-ISR group (
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.